# Oncolys BioPharma

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/oncolys-biopharma

- Industry: Pharmaceuticals
- Headquarters: Tokyo, Japan
- Website: www.oncolys.com
- Total disclosed funding: $22M
- Latest round: Series C (Oct 31, 2006)
- Investors on record: 5

## About

Oncolys BioPharma Inc. is a biopharmaceutical company engaged in the research and development of innovative therapeutics, focusing primarily on oncology and infectious diseases through its proprietary technologies.Oncolys BioPharma Inc. was founded in 2004 and is headquartered in Tokyo, Japan. The company specializes in the development of therapeutic solutions for cancer and viral infections. In December 2013, Oncolys completed an IPO, raising JPY 6600 million by issuing 2.55 million shares at a price of JPY 2600 each, marking a significant milestone in its funding journey. The company has participated in five total deals since its inception.Oncolys BioPharma Inc. specializes in the research and development of innovative therapeutics, focusing on oncology and infectious diseases. The company’s core offerings include investigational cancer therapies targeting specific tumor markers to enhance treatment efficacy and minimize side effects. Its technology aims to provide personalized treatment protocols for diverse patient populations across North America, Europe, and parts of Asia. Oncolys also collaborates with healthcare providers and pharmaceutical companies to expand its reach and facilitate product development and distribution.In the most recent year, 2023, Oncolys BioPharma Inc. reported revenues of JPY 449,646.4, accompanied by an EBITDA of -JPY 13,745,686.6. The company generates revenue primarily through partnerships and collaborations, involving milestone payments, royalties, and revenue-sharing agreements related to its drug pipeline.Oncolys BioPharma Inc. is focusing on the development of new cancer and infectious disease therapies, with plans to launch several investigational products in the upcoming years. The company aims to expand its presence in North America and Europe by the end of 2025. The funds raised through the IPO in December 2013 will be utilized to support these initiatives, enhancing its capabilities in clinical development and market entry.

## Funding rounds

- Series C, Oct 31, 2006, $9.3M — Ant Capital Partners, Nomura Research Institute, Ltd.
- Series B, Sep 1, 2006, $13M — Mitsui Sumitomo Insurance Venture Capital, Icon Ventures, SMBC Venture Capital

## Investors

- Mitsui Sumitomo Insurance Venture Capital (https://capitalatlas.ai/funds/mitsui-sumitomo-insurance-venture-capital) — Series B
- Icon Ventures (https://capitalatlas.ai/funds/icon-ventures) — Series B
- SMBC Venture Capital (https://capitalatlas.ai/funds/smbc-venture-capital) — Series B
- Ant Capital Partners (https://capitalatlas.ai/funds/ant-capital-partners) — Series C
- Nomura Research Institute, Ltd. — Series C